Join Growin Stock Community!

Gri bio, inc.GRI.US Overview

US StockHealthcare
(No presentation for GRI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GRI AI Insights

GRI Overall Performance

GRI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GRI Recent Performance

-3.92%

Gri bio, inc.

0.05%

Avg of Sector

-0.31%

S&P500

GRI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GRI Key Information

GRI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GRI Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Price of GRI

GRI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GRI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-135.69
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.61
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
0.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-135.69
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.61
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
0.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is GRI's latest earnings report released?

    The most recent financial report for Gri bio, inc. (GRI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GRI's short-term business performance and financial health. For the latest updates on GRI's earnings releases, visit this page regularly.

  • How much debt does GRI have?

    As of the end of the reporting period, Gri bio, inc. (GRI) had total debt of 84K, with a debt ratio of 0.02. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does GRI have?

    At the end of the period, Gri bio, inc. (GRI) held Total Cash and Cash Equivalents of 4.06M, accounting for 0.85 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GRI's EPS continuing to grow?

    According to the past four quarterly reports, Gri bio, inc. (GRI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GRI?

    Gri bio, inc. (GRI)'s Free Cash Flow (FCF) for the period is -2.31M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1.98% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.